Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: RT 60 GY Clear all
Completed Phase 3 Interventional Results available

High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00533949
View directory record Official record
Conditions
Lung Cancer, Radiation Toxicity
Interventions
Cetuximab, Carboplatin, Paclitaxel, 60 Gy RT, 74 Gy RT
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
207
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 170 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Not applicable Interventional

TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck

NCT03729518
View directory record Official record
Conditions
Oropharyngeal Cancer, Squamous Cell Carcinoma, Human Papilloma Virus
Interventions
Radiation Therapy (IMRT or IMPT)
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 25, 2026, 6:27 AM EDT
Terminated Phase 2 Interventional Results available

Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma

NCT02394665
View directory record Official record
Conditions
Glioblastoma
Interventions
Intensity Modulated Radiation Therapy, Temozolomide, Functional Assessment of Cancer Therapy-Brain (FACT-Br), Stereotactic Radiosurgery Boost, Simultaneous Integrated Boost, 3D MRSI
Radiation · Drug · Behavioral + 1 more
Lead sponsor
University of Miami
Other
Eligibility
19 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Sep 25, 2026, 6:27 AM EDT
Not listed Phase 1 Interventional

CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

NCT00768911
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
CT-322, Temozolomide, Radiation Therapy
Drug · Procedure
Lead sponsor
Adnexus, A Bristol-Myers Squibb R&D Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Little Rock, Arkansas • Chicago, Illinois • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2010 · Synced Sep 25, 2026, 6:27 AM EDT
Withdrawn Phase 2 Interventional

RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

NCT04849377
View directory record Official record
Conditions
Human Papillomavirus (HPV), Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
RT 50 Gy, RT 54 GY, RT 60 GY, Induction Therapy, Carboplatin, Cisplatin 200, Cisplatin 240
Radiation · Other · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

NCT03532295
View directory record Official record
Conditions
Glioma, Glioblastoma
Interventions
Epacadostat, Bevacizumab, Radiation therapy, Retifanlimab
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Phoenix, Arizona • Rochester, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

NCT03345095
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma
Interventions
Marizomib, Temozolomide, radiotherapy
Drug · Radiation
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
749 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
9
States / cities
Scottsdale, Arizona • Orange, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 1 Interventional

Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma

NCT00502411
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Doxorubicin, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer

NCT02908477
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
Adjuvant Radiation Therapy, Docetaxel, Cisplatin
Radiation · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Early Phase 1 Interventional

Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC

NCT05873439
View directory record Official record
Conditions
Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
Interventions
Genomically Guided Radiation Therapy (RT)
Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 25, 2026, 6:27 AM EDT
Terminated Phase 1Phase 2 Interventional

Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM

NCT02085304
View directory record Official record
Conditions
Glioblastoma
Interventions
Gross total resection and Gliadel(R) wafers implanted, GammaKnife(R) stereotactic Radiosurgery, Standard fractionated radiation therapy, Temozolomide
Procedure · Radiation · Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

NCT02715609
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Disulfiram, Copper Gluconate, Surgery, Radiation, Temozolomide
Drug · Procedure · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 25, 2026, 6:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas

NCT05768919
View directory record Official record
Conditions
Glioblastoma
Interventions
Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a
Drug
Lead sponsor
SignPath Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 25, 2026, 6:27 AM EDT
Recruiting Early Phase 1 Interventional

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

NCT06831526
View directory record Official record
Conditions
Glioblastoma
Interventions
Azeliragon, Temozolomide, Radiation therapy, Surgery or LITT
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 25, 2026, 6:27 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT02179086
View directory record Official record
Conditions
Glioblastoma
Interventions
Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Temozolomide
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
230
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 179 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 25, 2026, 6:27 AM EDT
Recruiting Phase 2 Interventional

A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)

NCT05894083
View directory record Official record
Conditions
Oropharyngeal Cancer, Squamous Cell Carcinoma of the Oropharynx
Interventions
Surgery, Chemoradiation, Observation, Post-operative radiation
Procedure · Combination Product · Other + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT02186847
View directory record Official record
Conditions
Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Interventions
Radiation Therapy, Carboplatin, Metformin, Paclitaxel
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
219
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Auburn, California + 176 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 25, 2026, 6:27 AM EDT
Recruiting Phase 2 Interventional

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique

NCT05045950
View directory record Official record
Conditions
Brain Metastases
Interventions
Memantine -Twice Daily or Extended Release, WBRT utilizing the PRDR technique
Drug · Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 1 Interventional

RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas

NCT02871843
View directory record Official record
Conditions
Glioblastoma, Oligodendroglioma, Anaplastic Oligodendroglioma
Interventions
RRx-001 dose escalation with TMZ + RT, Radiation, Fixed dose Temozolomide (75 mg/m2), TMZ Maintenance
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
San Francisco, California • New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 25, 2026, 6:27 AM EDT
Completed No phase listed Observational

PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients

NCT03342378
View directory record Official record
Conditions
Squamous Cell Carcinoma, Oropharynx Cancer
Interventions
Intensity modulated radiotherapy (IMRT), PET-MRI
Radiation · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Sep 25, 2026, 6:27 AM EDT
Recruiting Phase 1 Interventional

Atovaquone Combined With Radiation in Children With Malignant Brain Tumors

NCT06624371
View directory record Official record
Conditions
High-grade Glioma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
Atovaquone, Radiation Therapy
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
2 Years to 25 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer

NCT00369122
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7
Interventions
Bevacizumab, Cisplatin, External Beam Radiation Therapy, Internal Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
103
States / cities
Burbank, California • Sacramento, California • Colorado Springs, Colorado + 73 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Celecoxib and Radiation Therapy in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT00046839
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
44
States / cities
Colorado Springs, Colorado • Gainesville, Florida • Jacksonville, Florida + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 25, 2026, 6:27 AM EDT
Terminated Phase 2 Interventional Results available

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT01822496
View directory record Official record
Conditions
Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Interventions
Radiation Therapy, Carboplatin, Cisplatin, Crizotinib, Erlotinib, Etoposide, Paclitaxel
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
174
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 137 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2019 · Synced Sep 25, 2026, 6:27 AM EDT